Ihre
gewählte
Nachricht : |
|
| Datum : | 15.05.2014 |
Titel : |
DGAP-Adhoc: Pulsion Medical Systems SE: Consensus reached regarding Conclusion of Domination and Profit Transfer Agreement between MAQUET Medical Systems AG and Pulsion Medical Systems SE; Downlisting |
| Meldung : | Pulsion Medical Systems SE / Key word(s): Miscellaneous 15.05.2014 18:39 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Pulsion Medical Systems SE: Consensus reached regarding Conclusion of Domination and Profit Transfer Agreement between MAQUET Medical Systems AG and Pulsion Medical Systems SE; Downlisting Feldkirchen, May 15, 2014 - Today, the Management Board of MAQUET Medical Systems AG (former: Alsterhöhe 1. V V AG, in the following referred to as: "MAQUET") - with the approval of the Supervisory Board -and the Administrative Board of Pulsion Medical Systems SE (ISIN: DE0005487904 / WKN 548790, in the following referred to as "Pulsion") agreed to prepare a domination and profit transfer agreement between MAQUET, as the controlling entity, and Pulsion, as the controlled entity, and to conclude such agreement. An offer will be made to the minority shareholders of Pulsion to acquire their shares against cash compensation, and the minority shareholders of Pulsion will be offered a compensation payment for the duration of the agreement. The companies will determine the final structure of the provisions regarding the cash compensation and the annual compensation payment under the agreement on the basis of a company valuation and in accordance with legal requirements. The agreement requires- amongst others- the approval of the shareholders meetings of both companies to be valid. The Administrative Board of Pulsion Medical Systems SE further concluded, that they will apply to the management of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) for a revocation of the admission to trading of the shares from the Regulated Market (Regulierter Markt) ("downlisting"). After such revocation, the shares may only be traded on the open market ("Freiverkehr"). Important notice: This information contains forward-looking statements that are based upon current views and assumptions of Pulsion, which were made to its best knowledge. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors. In consideration of these risks, uncertainties and other factors, persons receiving these documents are advised not to unreasonably rely on these forward-looking statements. Contact: Investor Relations PULSION Medical Systems SE Ralph Schäfer Director Legal Affairs Tel.: +49 (0)89 / 459914 211 Fax: +49 (0)89 / 459914 481 E-mail: schaefer@pulsion.com --------------------------------------------------------------------------- Language: English Company: Pulsion Medical Systems SE Hans- Riedl- Straße 21 85622 Feldkirchen Germany Phone: +49 (0)89 4599 14-0 Fax: +49 (0)89 4599 14-18 E-mail: info@pulsion.com Internet: www.pulsion.com ISIN: DE0005487904 WKN: 548790 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service --------------------------------------------------------------------------- |
| Sender : | Homepage |